YAP1 and metabolic dysfunction-associated steatotic liver disease: While both inhibitors and activators have the potential to contribute substantially to the management of liver tumors and other complications, such as MASLD, the discovery and optimization of such modulators of YAP/TAZ signaling represents a promising frontier in the treatment of liver disease.